Список использованных источников
1. What Is Prehistoric Medicine? Available at: https://www.medicalnewstoday.com/info/medicine/prehistoric-medicine.php. (Accessed: 7th September 2018)
2. Hardy, K., Buckley, S. & Huffman, M. Neanderthal self-medication in context. Antiquity 87, 873–878 (2013).
3. McKay, D. L. & Blumberg, J. B. A Review of the bioactivity and potential health benefits of chamomile tea (Matricaria recutita L.). Phyther. Res. 20, 519–530 (2006).
4. Finch, C. E. Evolution of the human lifespan and diseases of aging: Roles of infection, inflammation, and nutrition. Proc. Natl. Acad. Sci. U. S. A. 107, 1718–1724 (2010).
5. Первобытные нейрохирурги: с ритуалами и без анестезии – Антропогенез. РУ. Available at: http://antropogenez.ru/interview/961/. (Accessed: 7th September 2018)
6. Ramirez Rozzi, F. & Froment, A. Earliest Animal Cranial Surgery: from Cow to Man in the Neolithic. Sci. Rep. 8, 5536 (2018).
7. Museum: House of Life. Available at: http://www.ucl.ac.uk/museums-static/digitalegypt/museum/museum2.html. (Accessed: 7th September 2018)
8. Herodotus, The Histories, Book 2, chapter 77, section 2. Available at: http://www.perseus.tufts.edu/hopper/text?doc=Perseus%3Atext%3A1999.01.0126%3Abook%3D2%3Achapter%3D77%3Asection%3D2. (Accessed: 7th September 2018)
9. Herodotus, The Histories, Book 2, chapter 77, section 3. Available at: http://www.perseus.tufts.edu/hopper/text?doc=Perseus%3Atext%3A1999.01.0126%3Abook%3D2%3Achapter%3D77%3Asection%3D3. (Accessed: 7th September 2018)
10. Hajar, R. History of medicine timeline. Heart Views 16, 43–5 (2015).
11. Ayurvedic Medicine: In Depth | NCCIH. Available at: https://nccih.nih.gov/health/ayurveda/introduction.htm#hed5. (Accessed: 7th September 2018)
12. Traditional Chinese Medicine: In Depth | NCCIH. Available at: https://nccih.nih.gov/health/whatiscam/chinesemed.htm. (Accessed: 7th September 2018)
13. Федеральный закон от 21.11.2011 № 323-ФЗ. Статья 71. Клятва врача. Available at: http://www.consultant.ru/document/cons_doc_LAW_121895/7f8181673a3d85e7a31b0c55b949fa3da8974b5b/. (Accessed: 7th September 2018)
14. Nutton, V. Ancient medicine.
15. Wallis, F. Medieval medicine : a reader.
16. Debunking a myth – Harvard Gazette. Available at: https://news.harvard.edu/gazette/story/2011/04/debunking-a-myth/. (Accessed: 7th September 2018)
17. Ghannaee Arani, M. et al. Ibn Sina’s (Avicenna) Contributions in the Treatment of Traumatic Injuries. Trauma Mon. 17, 301–4 (2012).
18. Moosavi, J. The place of Avicenna in the history of medicine. Avicenna J. Med. Biotechnol. 1, 3–8 (2009).
19. Madigan, M. T. & Martinko, J. Brock Biology of Micro-Organisms Brock Biology of Microorganisms. (1997).
20. Vargesson, N. Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res. C. Embryo Today 105, 140–56 (2015).
21. Stephens, T. D., Bunde, C. J. & Fillmore, B. J. Mechanism of action in thalidomide teratogenesis. Biochem. Pharmacol. 59, 1489–99 (2000).
22. Merker, H. J., Heger, W., Sames, K., Stürje, H. & Neubert, D. Embryotoxic effects of thalidomide-derivatives in the non-human primate Callithrix jacchus. I. Effects of 3-(1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-dioxopiperidine (EM12) on skeletal development. Arch. Toxicol. 61, 165–79 (1988).
23. Latif, T., Chauhan, N., Khan, R., Moran, A. & Usmani, S. Z. Thalidomide and its analogues in the treatment of Multiple Myeloma. Exp. Hematol. Oncol. 1, 27 (2012).
24. Rehman, W., Arfons, L. M. & Lazarus, H. M. The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development. Ther. Adv. Hematol. 2, 291–308 (2011).
25. Ecklund, E. H., Johnson, D. R., Scheitle, C. P., Matthews, K. R. W. & Lewis, S. W. Religion among Scientists in International Context. Socius Sociol. Res. a Dyn. World 2, 237802311666435 (2016).
26. Scientists and Belief | Pew Research Center. Available at: http://www.pewforum.org/2009/11/05/scientists-and-belief/#fn-12952-1. (Accessed: 10th November 2018)
27. Принципы надлежащей лабораторной практики. (Стандартинформ, 2015).
28. ГОСТ Р 52249-2009 Правила производства и контроля качества лекарственных средств. Available at: http://www.vashdom.ru/gost/52249-2009/. (Accessed: 1st November 2018)
29. Willingham, E. Of lice and men: An itchy history. Scientific American (2011).
30. Han, H. et al. Association of genetic polymorphisms in ADH and ALDH2 with risk of coronary artery disease and myocardial infarction: A meta-analysis. Gene 526, 134–141 (2013).
31. WHO | Breast cancer: prevention and control. WHO (2016).
32. Широкова И. & Прожерина Ю. Рак молочной железы: взгляд экспертов. Ремедиум. Журнал о российском рынке лекарств и медицинской технике (2016).
33. Демография::Федеральная служба государственной статистики. Available at: http://www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/population/demography/#. (Accessed: 11th November 2019)
34. Клинические рекомендации РООМ. Available at: http://breastcancersociety.ru/rek/view/201. (Accessed: 11th November 2018)
35. Oeffinger, K. C. et al. Breast Cancer Screening for Women at Average Risk. JAMA 314, 1599 (2015).
36. Breast Cancer in Young Women. Available at: https://www.webmd.com/breast-cancer/breast-cancer-young-women#1. (Accessed: 11th November 2018)
37. Ferzoco, R. M. & Ruddy, K. J. The Epidemiology of Male Breast Cancer. Curr. Oncol. Rep. 18, 1 (2016).
38. Controversies in Mammography Screening. Available at: https://www.medscape.com/viewarticle/430076. (Accessed: 11th November 2018)
39. Mammograms: Benefits and Risks. Available at: https://www.breastcancer.org/symptoms/testing/types/mammograms/benefits_risks. (Accessed: 11th November 2018)
40. Bashir, M. N. Epidemiology of Prostate Cancer. Asian Pac. J. Cancer Prev. 16, 5137–41 (2015).
41. Tsodikov, A. et al. Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. Ann. Intern. Med. 167, 449 (2017).
42. Prostate Cancer Screening Guidelines | Memorial Sloan Kettering Cancer Center. Available at: https://www.mskcc.org/cancer-care/types/prostate/screening/screening-guidelines-prostate. (Accessed: 12th November 2018)
43. Общероссийский союз общественных объединений. Ассоциация онкологов России. Клинические рекомендации по диагностике и лечению рака предстательной железы. (2014).
44. Российское общество урологов, Ассоциация онкологов России & Российское общество онкоурологов. Клинические рекомендации: рак предстательной железы. (2016).
45. Ilic, D., Neuberger, M. M., Djulbegovic, M. & Dahm, P. Screening for prostate cancer. Cochrane Database Syst. Rev. (2013). doi:10.1002/14651858.CD004720.pub3
46. Rothwell, P. M. et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376, 1741–1750 (2010).
47. Chen, J. et al. Identification of a novel TIF-IA – NF-κB nucleolar stress response pathway. Nucleic Acids Res. 46, 6188–6205 (2018).
48. Hudson, A. L. & Colvin, E. K. Transgenic Mouse Models of SV40-Induced Cancer. ILAR J. 57, 44–54 (2016).
49. Council, I. of M. and N. R. Use of Laboratory Animals in Biomedical and Behavioral Research. (National Academies Press, 1988). doi:10.17226/1098
50. Malhi, G. S., Tanious, M., Das, P., Coulston, C. M. & Berk, M. Potential Mechanisms of Action of Lithium in Bipolar Disorder. CNS Drugs 27, 135–153 (2013).
51. Lithium’s Mechanism of Action – A Focus on Neuroprotection. 23, (2017).
52. Lithium’s Hypothetical Mechanism of Action. Available at: https://www.youtube.com/watch?v=iNH0GdldxYs. (Accessed: 5th January 2019)
53. Shorter, E. The history of lithium therapy. Bipolar Disord. 11 Suppl 2, 4–9 (2009).
54. Nikiphorou, E., Uksila, J. & Sokka, T. A cross-sectional study of vitamin D levels in a large cohort of patients with rheumatic diseases. Clin. Rheumatol. 37, 803–810 (2018).
55. Ilic, M. & Ilic, I. Epidemiology of pancreatic cancer. World J. Gastroenterol. 22, 9694–9705 (2016).
56. Streicher, S. A., Yu, H., Lu, L., Kidd, M. S. & Risch, H. A. Case-Control Study of Aspirin Use and Risk of Pancreatic Cancer. Cancer Epidemiol. Biomarkers Prev. 23, 1254–1263 (2014).
57. Framingham Heart Study. Available at: https://www.framinghamheartstudy.org/. (Accessed: 10th January 2019)
58. Framingham Risk Score for Hard Coronary Heart Disease. doi:10.1056/NEJM199006073222304
59. SCORE Risk Charts. Available at: https://www.escardio.org/Education/Practice-Tools/CVD-prevention-toolbox/SCORE-Risk-Charts. (Accessed: 18th December 2017)
60. NHS3 – Looking forward, connecting to the past. Available at: http://nhs2survey.org/wordpress/. (Accessed: 10th January 2019)
61. Lynch, J. J., Frederick Fregin, G., Mackie, J. B. & Monroe, R. R. Heart Rate Changes in the Horse to Human Contact. Psychophysiology 11, 472–478 (1974).
62. Keller, A., Akintola, T. & Colloca, L. Placebo Analgesia in Rodents: Current and Future Research. Int. Rev. Neurobiol. 138, 1–15 (2018).
63. Grevert, P., Albert, L. H. & Goldstein, A. Partial antagonism of placebo analgesia by naloxone. Pain 16, 129–43 (1983).
64. Benedetti, F. The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia. Pain 64, 535–43 (1996).
65. Levine, J. D., Gordon, N. C. & Fields, H. L. The mechanism of placebo analgesia. Lancet (London, England) 2, 654–7 (1978).
66. Price, D. D., Craggs, J., Nicholas Verne, G., Perlstein, W. M. & Robinson, M. E. Placebo analgesia is accompanied by large reductions in pain-related brain activity in irritable bowel syndrome patients. Pain 127, 63–72 (2007).
67. Wager, T. D. et al. Placebo-Induced Changes in fMRI in the Anticipation and Experience of Pain. Science (80-.). 303, 1162–1167 (2004).
68. Wager, T. D., Scott, D. J. & Zubieta, J.-K. Placebo effects on human mu-opioid activity during pain. Proc. Natl. Acad. Sci. U. S. A. 104, 11056–61 (2007).
69. de la Fuente-Fernández, R., Lidstone, S. & Stoessl, A. J. Placebo effect and dopamine release. J. Neural Transm. Suppl. 415–8 (2006).
70. Wager, T. D. & Atlas, L. Y. The neuroscience of placebo effects: connecting context, learning and health. Nat. Rev. Neurosci. 16, 403–18 (2015).
71. Häuser, W., Hansen, E. & Enck, P. Nocebo Phenomena in Medicine. Dtsch. Ärzteblatt Int. 109, 459–65 (2012).
72. Petrie, K. J. & Rief, W. Psychobiological Mechanisms of Placebo and Nocebo Effects: Pathways to Improve Treatments and Reduce Side Effects. Annu. Rev. Psychol. 70, 599–625 (2019).
73. Crichton, F., Dodd, G. expectations produce symptoms from infrasound associated with wind turbines?orge, Schmid, G., Gamble, G. & Petrie, K. J. Can expectations produce symptoms from infrasound associated with wind turbines? Heal. Psychol. 33, 360–364 (2014).
74. Cannon, C. P. et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. N. Engl. J. Med. 350, 1495–1504 (2004).
75. Perkins, G. D. et al. A Randomized Trial of Epinephrine in Out-of-Hospital Cardiac Arrest. N. Engl. J. Med. 379, 711–721 (2018).
76. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. & PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 6, e1000097 (2009).
77. Moher, D., Tetzlaff, J., Tricco, A. C., Sampson, M. & Altman, D. G. Epidemiology and Reporting Characteristics of Systematic Reviews. PLoS Med. 4, e78 (2007).
78. Shojania, K. G. et al. How Quickly Do Systematic Reviews Go Out of Date? A Survival Analysis. Ann. Intern. Med. 147, 224 (2007).
79. Health On the Net (HON): HONcode: Principles in Russian. Available at: http://www.hon.ch/HONcode/Webmasters/Russian/. (Accessed: 29th October 2018)
80. Грипп. Available at: https://www.who.int/ru/news-room/fact-sheets/detail/influenza-(seasonal). (Accessed: 25th October 2018)
81. Influenza (Flu) Antiviral Drugs and Related Information | FDA. Available at: https://www.fda.gov/drugs/information-drug-class/influenza-flu-antiviral-drugs-and-related-information. (Accessed: 29th October 2018)
82. Influenza Antiviral Medications: Summary for Clinicians. Centers for Disease Control and Prevention Available at: https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm. (Accessed: 29th October 2018)
83. What You Should Know About Flu Antiviral Drugs | CDC. Available at: https://www.cdc.gov/flu/treatment/whatyoushould.htm. (Accessed: 29th October 2018)
84. Эффективность и безопасность гепатопротекторов с точки зрения доказательной медицины. Available at: http://health-ua.com/article/15676-effektivnost-i-bezopasnost-gepatoprotektorov-s-tochki-zreniya-dokazatelnoj-. (Accessed: 29th October 2018)
85. Saito, Z. et al. Effectiveness of hepatoprotective drugs for anti-tuberculosis drug-induced hepatotoxicity: a retrospective analysis. BMC Infect. Dis. 16, 668 (2016).
86. Rambaldi, A., Jacobs, B. P. & Gluud, C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. CochraneDatabase Syst. Rev. (2007). doi:10.1002/14651858.CD003620.pub3
87. Day, P. et al. Клинические рекомендации EASL – EASD – EASO по диагностике и лечению неалкогольной жировой болезни печени (2016).
88. Ivashkin, V. et al. Diagnostics and treatment of non-alcoholic fatty liver disease: clinical guidelines of the Russian Scientific Liver Society and the Russian gastroenterological association. Vshtspb.Ru 24–42 (2013).
89. Elia, V. et al. Permanent physico-chemical properties of extremely diluted aqueous solutions of homeopathic medicines. Homeopathy 93, 144–50 (2004).
90. Kayne, S. B. Homeopathic pharmacy : theory and practice. (Elsevier Churchill Livingstone, 2006).
91. Chakraborti, D. et al. Arsenic toxicity from homeopathic treatment. J. Toxicol. Clin. Toxicol. 41, 963–7 (2003).
92. HRI – Homeopathy use around the world. Available at: https://www.hri-research.org/resources/essentialevidence/use-of-homeopathy-across-the-world/. (Accessed: 29th October 2018)
93. Dantas, F. et al. A systematic review of the quality of homeopathic pathogenetic trials published from 1945 to 1995. Homeopathy 96, 4–16 (2007).
94. Junod, S. W. An alternative perspective: homeopathic drugs, Royal Copeland, and federal drug regulation. Food Drug Law J. 55, 161–83 (2000).
95. Воробьев П. А., Безмельницына Л. Ю., Краснова Л. С. & Холовня М. А. Оценка медицинской технологии применения лекарственных препаратов с ноотропным и психостимулирующим действием: кортексин, пирацетам, цитиколин, церебролизин. Клиническаягеронтология 53–73 (2017).
96. Flicker, L. & Grimley Evans, J. Piracetam for dementia or cognitive impairment. Cochrane Database Syst. Rev. (2004). doi:10.1002/14651858.CD001011
97. Cerebrolysin | EVER Pharma. Available at: https://www.everpharma.com/portfolio/neurology/cerebrolysin/. (Accessed: 29th October 2018)
98. Vastag, B. Biotechnology: Crossing the barrier. Nature 466, 916–918 (2010).
99. Chen, N. et al. Cerebrolysin for vascular dementia. Cochrane Database Syst. Rev. (2013). doi:10.1002/14651858.CD008900.pub2
100. Ziganshina, L. E., Abakumova, T. & Vernay, L. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst. Rev. (2017). doi:10.1002/14651858.CD007026.pub5
101. Смирнова М. Д. & Агеев Ф. Т. Статины – старые мифы и новые факты. Регулярныевыпуски‘РМЖ’ 1421–1428 (2017).
102. Chasman, D. I. et al. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291, 2821–7 (2004).
103. Liao, J. K. Safety and efficacy of statins in Asians. Am. J. Cardiol. 99, 410–4 (2007).
104. Stroes, E. S. et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur. Heart J. 36, 1012–22 (2015).
105. Kashani, A. et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 114, 2788–97 (2006).
106. Riaz, H. et al. Meta-analysis of Placebo-Controlled Randomized Controlled Trials on the Prevalence of Statin Intolerance. Am. J. Cardiol. 120, 774–781 (2017).
107. McGuinness, B., Craig, D., Bullock, R. & Passmore, P. Statins for the prevention of dementia. Cochrane Database Syst. Rev. (2016). doi:10.1002/14651858.CD003160.pub3
108. O’Donoghue, M. et al. Lipoprotein-Associated Phospholipase A 2 and Its Association With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy – Thrombolysis In Myocardial Infarction) Trial. Circulation 113, 1745–1752 (2006).
109. Taylor, F. et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst. Rev. (2013). doi:10.1002/14651858.CD004816.pub5
110. Silva, M. A., Swanson, A. C., Gandhi, P. J. & Tataronis, G. R. Statin-related adverse events: A meta-analysis. Clin. Ther. 28, 26–35 (2006).
111. Finegold, J. A., Manisty, C. H., Goldacre, B., Barron, A. J. & Francis, D. P. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur. J. Prev. Cardiol. 21, 464–474 (2014).
112. Galluzzi, L. et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 25, 486–541 (2018).
notes
